Case Report of Hepatic Mucormycosis After Liver Transplantation: Successful Treatment With Liposomal Amphotericin B Followed by Posaconazole Sequential Therapy

Abboud, Cely Saad; Bergamasco, Maria Daniela; Baía, Carlos Eduardo Sandoli; Lallee, M.P.; Zan, A.S.C.; Zamorano, Mabel M. Barros; Pereira, Osvaldo José Ribeiro; Mies, Sérgio

doi:10.1016/j.transproceed.2012.07.042

Cited by 18 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantages of the oral formulation is that it allows earlier patient discharge and decreases relapse with prolonged administration. 49,50 In a single prospective study of 21 patients refractory or intolerant to AmB, a good response was reported with posaconazole, with the exception of patients with disseminated disease. 51 Posaconazole is recommended as second-line treatment for patients with refractory disease or intolerance to AmB or for those who need prolonged treatment maintenance.…”

Section: Treatmentmentioning

confidence: 99%

Cutaneous mucormycosis

Castrejón-Pérez

Welsh

Miranda

et al. 2017

An. Bras. Dermatol.

136

168

View full text Add to dashboard Cite

Cutaneous mucormycosis is an emerging fungal infection caused by opportunistic fungi of the phylum Glomeromycota. It is frequent in poorly controlled diabetic patients and individuals with immunosuppression. It is usually acquired by direct inoculation through trauma. The clinical presentation is nonspecific, but an indurated plaque that rapidly evolves to necrosis is a common finding. Diagnosis should be confirmed by demonstration of the etiological agent and new molecular diagnostic tools have recently been described. It is an invasive life-threatening disease and in order to improve survival, a prompt diagnosis and multidisciplinary management should be provided. The treatment of choice is amphotericin B, but new azoles, such as posaconazole and isavuconazole, must be considered.

show abstract

Section: Treatmentmentioning

confidence: 99%

Cutaneous mucormycosis

Castrejón-Pérez

Welsh

Miranda

et al. 2017

An. Bras. Dermatol.

136

168

View full text Add to dashboard Cite

show abstract

“…We found seventeen cases of isolated hepatic mucormycosis in the literature [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27], of which the majority had hematologic malignancy with associated neutropenia and/or cytotoxic chemotherapy. We identified only four cases of isolated hepatic mucormycosis in solid organ transplant recipients, of whom three had liver transplants and one had a kidney transplant ( Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…However, in our patient along with other similar cases in Table 1, there was no evidence of other organ involvement. In the case of Abboud et al, the authors surmised the source was possibly donor derived as the liver donor was a prior kidney transplant recipient on immunosuppression [22]. Mekeel et al were unable to find an obvious source for the infection as the transplanted kidney did not have evidence of mucormycosis on pathology [16].…”

Section: Discussionmentioning

confidence: 99%

Isolated Hepatic Mucormycosis in the Early Post-Transplant Period: A Case Report and Literature Review

Santos¹,

Proia²

2019

obm transplant

View full text Add to dashboard Cite

Mucormycosis is a rare fungal infection associated with high morbidity and mortality that typically afflicts immunocompromised hosts. We present a case of isolated hepatic mucormycosis with Rhizopus spp. that developed in the early post-transplant period. Initial presentation was concerning for allograft rejection, but definitive diagnosis was made with histopathology and fungal culture. The patient had a favourable outcome with surgical resection, a course of liposomal amphotericin B combined with micafungin, and chronic suppressive therapy with posaconazole. We encountered only four cases of isolated hepatic mucormycosis in solid organ transplant recipients in the literature that presented as either fungal abscess or surgical anastomosis rupture. This case report and literature review demonstrates the need for urgent diagnosis and management of this uncommon condition and outlines an effective therapeutic regimen.

show abstract

“…They include ketoacidosis and uncontrolled diabetes mellitus [2], renal failure [3], solid tumors [4, 5], acquired or congenital neutropenia [6], immunosuppressive therapy [7], and solid organ transplantation [8]. Healthcare-associated mucormycosis [9] has also been reported in relation to ostomy bags, adhesive bandages, and wooden tongue depressors.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Mucormycosis: An Emerging Infection

Muqeetadnan

Rahman

Amer

et al. 2012

Case Reports in Pulmonology

View full text Add to dashboard Cite

Mucormycosis is a rare, but emerging, life-threatening, rapidly progressive, angioinvasive fungal infection that usually occurs in immunocompromised patients. We present a case of pulmonary mucormycosis in a diabetic patient who was on chronic steroid therapy for ulcerative colitis. Early recognition of this diagnosis, along with aggressive management, is critical to effective therapy and patient survival. The delay in diagnosis of this rapidly progressive infection can result in mortality.

show abstract

Case Report of Hepatic Mucormycosis After Liver Transplantation: Successful Treatment With Liposomal Amphotericin B Followed by Posaconazole Sequential Therapy

Cited by 18 publications

References 6 publications

Cutaneous mucormycosis

Cutaneous mucormycosis

Isolated Hepatic Mucormycosis in the Early Post-Transplant Period: A Case Report and Literature Review

Pulmonary Mucormycosis: An Emerging Infection

Contact Info

Product

Resources

About